FDA approves 7.2 mg Wegovy HD under accelerated voucher program
A higher-dose version of the Wegovy injection is now approved in the US, offering more weight loss than the 2.4 mg dose along with a higher rate of one nerve-related side effect.
The FDA approved semaglutide 7.2 mg injection (Wegovy HD; Novo Nordisk) for long-term reduction of excess body weight in adults with obesity, or overweight with at least one weight-related condition, Novo Nordisk announced on March 19, 2026 [2]. It is the first GLP-1 receptor agonist cleared under the Commissioner's National Priority Voucher pilot program and the fourth product approved through that pathway [2]. Novo Nordisk said a US launch in a single-dose pen is expected in April 2026 [2].
The decision rests on the phase 3 STEP UP program. In STEP UP, 1,407 adults with obesity were randomly assigned to weekly semaglutide 7.2 mg, 2.4 mg, or placebo, all with lifestyle intervention, and followed for 72 weeks [2]. The 7.2 mg dose produced a mean weight loss of 18.7%, compared with 3.9% for placebo, and 31.2% of participants lost at least 25% of their body weight [2]. Novo Nordisk cited a mean weight loss of 20.7% for the higher dose [2], and those who stayed on treatment for the full trial lost nearly 21% of their starting body weight [1].
Until now, the highest Wegovy injection dose sold in the US was 2.4 mg, and the 7.2 mg dose was under FDA review [1].
A second trial, STEP UP T2D, enrolled about 512 adults with obesity and type 2 diabetes in the same three treatment groups [2]. The 7.2 mg dose produced 13.2% mean weight loss, and 21.3% of patients lost 20% or more of their body weight [2]. Updated results from both trials were published in The Lancet Diabetes & Endocrinology in November 2025 [2].
Safety was consistent with earlier semaglutide trials and comparable to the 2.4 mg dose, with gastrointestinal events the most common side effects [2]. One difference stood out: dysesthesia, an abnormal sensation such as tingling or burning, was reported in 18.9% of people taking 7.2 mg in STEP UP T2D, compared with 4.9% at 2.4 mg and 0% on placebo [2].
The 7.2 mg dose joins a US Wegovy portfolio that also includes a 25 mg once-daily pill and weekly injections of 1.7 mg and 2.4 mg [2]. It is already approved in the European Union and the United Kingdom [2].
"The new FDA is moving with unprecedented efficiency on products that advance national priorities," FDA Commissioner Martin Makary said in a statement [2]. Novo Nordisk CEO Mike Doustdar said the company's goal is to "help even more people reach their weight and health goals" [2].
Why it matters for patients
For adults who have not lost enough weight on the 2.4 mg Wegovy injection, the 7.2 mg dose offers another step within the same drug class before options such as bariatric surgery are considered [2]. The trade-off shown in the trials is more weight loss at the higher dose alongside a higher rate of dysesthesia, and the STEP UP T2D results suggest the gap between the two doses is wider in people who also have type 2 diabetes [2].
The trial data come from people who received the drug plus lifestyle intervention, so the results reflect that combination rather than the medication alone [2]. Whether the higher dose is covered by insurance, what it costs, and how clinicians decide who should move up from 2.4 mg have not been disclosed [2].
What happens next
Novo Nordisk expects to launch Wegovy HD in the US in April 2026 in a single-dose pen [2]. The 7.2 mg dose was reviewed under the Commissioner's National Priority Voucher program, which the FDA has used for a small number of products [2]. Details on pricing, insurance coverage, and any further trial results for the higher dose have not been reported [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.